Korean LG Life Sciences and Swiss Biopartners Announce Positive Phase III Results For Once-Weekly Somatropin Biosimilar
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's LG Life Science and Swiss Biopartners GmbH will separately file biologics license applications in early 2010 with U.S. FDA and EMEA for their jointly developed slow-release recombinant human growth hormone somatropin